Ranbaxy to co-market Ferrings' urology drug

Ranbaxy Laboratories has entered into a co-marketing agreement with Switzerland-based Ferring International, a speciality biopharmaceutical company, for the latter's product Desmopressin.

The Ferring urology drug is used in the treatment of nocturia, a condition commonly seen in paediatric and geriatric patients.

Desmopressin, a structural analogue of the pituitary hormone Arginine Vasopressin, is an original research product of Ferring International.

Available in tablet and spray form, it is currently marketed by the company's subsidiary in India. The new co-marketing agreement aims to leverage Ranbaxy's marketing and distribution strengths to maximise patient coverage within the country. The product will be sold under the brand name, Adiuretin.

Sanjeev Dani, regional director "� India & Middle East, Ranbaxy, said: "This is a strategic move by Ranbaxy to in-licence differentiated products for the Indian market."

Ferring, a Swiss-based multinational company with operating subsidiaries in 40 countries, specialises in the biopharmaceutical segment. It employs more than 2,200 employees.

The company identifies, develops and markets innovative products in the area of urology, infertility, obstetrics, gastroenterology and endocrinology.

It recorded sales of approximately ¤598 million in 2003.